- Home
- WIW vs ITOS Comparison
WIW vs ITOS Comparison
Compare WIW & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIW
- ITOS
- Stock Information
- Founded
- WIW 2004
- ITOS 2011
- Country
- WIW United States
- ITOS United States
- Employees
- WIW N/A
- ITOS 173
- Industry
- WIW Finance Companies
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WIW Finance
- ITOS Health Care
- Exchange
- WIW Nasdaq
- ITOS Nasdaq
- Market Cap
- WIW 540.9M
- ITOS 450.9M
- IPO Year
- WIW N/A
- ITOS 2020
- Fundamental
- Price
- WIW $8.91
- ITOS $10.19
- Analyst Decision
- WIW
- ITOS Hold
- Analyst Count
- WIW 0
- ITOS 6
- Target Price
- WIW N/A
- ITOS $10.40
- AVG Volume (30 Days)
- WIW 229.9K
- ITOS 1.0M
- Earning Date
- WIW 01-01-0001
- ITOS 08-06-2025
- Dividend Yield
- WIW 11.14%
- ITOS N/A
- EPS Growth
- WIW N/A
- ITOS N/A
- EPS
- WIW N/A
- ITOS N/A
- Revenue
- WIW N/A
- ITOS N/A
- Revenue This Year
- WIW N/A
- ITOS N/A
- Revenue Next Year
- WIW N/A
- ITOS N/A
- P/E Ratio
- WIW N/A
- ITOS N/A
- Revenue Growth
- WIW N/A
- ITOS 177.89
- 52 Week Low
- WIW $8.01
- ITOS $4.80
- 52 Week High
- WIW $9.37
- ITOS $18.01
- Technical
- Relative Strength Index (RSI)
- WIW 63.57
- ITOS 60.66
- Support Level
- WIW $8.74
- ITOS $10.10
- Resistance Level
- WIW $8.87
- ITOS $10.22
- Average True Range (ATR)
- WIW 0.06
- ITOS 0.04
- MACD
- WIW 0.01
- ITOS -0.00
- Stochastic Oscillator
- WIW 98.82
- ITOS 78.57
About WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.